|Datasheet||Specific References||Reviews||Related Products||Protocols|
|Vector Type||Mammalian Expression Vector|
|Expression Method||Constiutive, Stable / Transient|
|Selection In Mammalian Cells||Hygromycin|
Human influenza hemagglutinin (HA) is a surface glycoprotein required for the infectivity of the human virus. The HA tag is derived from the HA-molecule corresponding to amino acids 98-106 has been extensively used as a general epitope tag in expression vectors. Many recombinant proteins have been engineered to express the HA tag, which does not appear to interfere with the bioactivity or the biodistribution of the recombinant protein. This tag facilitates the detection, isolation, and purification of the proteins.
The actual HA tag is as follows: 5' TAC CCA TAC GAT GTT CCA GAT TAC GCT 3' or 5' TAT CCA TAT GAT GTT CCA GAT TAT GCT 3' The amino acid sequence is: YPYDVPDYA.
|Rhesus TGFB2 ORF mammalian expression plasmid, C-GFPSpark tag||CG90036-ACG|
|Rhesus TGFB2 ORF mammalian expression plasmid, C-OFPSpark / RFP tag||CG90036-ACR|
|Rhesus TGFB2 ORF mammalian expression plasmid, C-Flag tag||CG90036-CF|
|Rhesus TGFB2 ORF mammalian expression plasmid, C-His tag||CG90036-CH|
|Rhesus TGFB2 ORF mammalian expression plasmid, C-Myc tag||CG90036-CM|
|Rhesus TGFB2 ORF mammalian expression plasmid, C-HA tag||CG90036-CY|
|Rhesus TGFB2 Gene cDNA clone plasmid||CG90036-G|
|Rhesus TGFB2 ORF mammalian expression plasmid, N-Flag tag||CG90036-NF|
|Rhesus TGFB2 ORF mammalian expression plasmid, N-His tag||CG90036-NH|
|Rhesus TGFB2 ORF mammalian expression plasmid, N-Myc tag||CG90036-NM|
|Rhesus TGFB2 ORF mammalian expression plasmid, N-HA tag||CG90036-NY|
|Rhesus TGFB2 natural ORF mammalian expression plasmid||CG90036-UT|
|Learn more about expression Vectors|
TGF beta 2 (Transforming growth factor beta 2), an extracellular glycosylated protein, which belongs to the TGF-beta family. TGF-beta regulates key mechanisms of tumor development, namely immunosuppression, metastasis, angiogenesis, and proliferation. TGF beta 2 suppression is a promising therapeutic approach for malignant tumor therapy. The signaling pathway of TGF beta 2/Smad plays an important role in the pathological process in posterior capsule opacification (PCO) after cataract surgery. Silencing Smad2 and Smad3 efficiently blocked the effect of TGF beta 2 on cell proliferation, migration, and extracellular matrix production. TGF beta 2 activation of MEKK3/ERK1/2/5 signaling modulates Has2 expression and hyaluronan (HA) production leading to the induction of epithelial to mesenchymal transformation (EMT) events. In addition, the upregulation of the TGF beta 2 level is a common pathological feature of Alzheimer's disease (AD) brains and suggests that it may be closely linked to the development of neuronal death related to AD.